A debilitating mental disorder, major depressive disorder is a leading cause of global
disease burden. Existing antidepressant drugs are not adequate for the majority of …

Depression is a well-known serious mental illness, and the onset of treatment using
traditional antidepressants is frequently delayed by several weeks. Moreover, numerous …

Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-
based antidepressant drugs are a primary line of treatment for this mental disorder, although …

Major depressive disorder (MDD) is a devastating psychiatric disorder which exacts
enormous personal and social-economic burdens. Ketamine, an N-methyl-D-aspartate …

Concurrent with recent insights into the neuroprogressive nature of depression, ketamine
shows promise in interfering with several neuroprogressive factors, and has been suggested …

Several recent studies have shown that a single intravenous subanesthetic dose of
ketamine, a NMDA receptor antagonist, exerts rapid antidepressant effects in patients with …

Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative
anesthetic ketamine induces rapid and sustained antidepressant actions. Although this …

Ketamine is a versatile agent primarily utilized as a dissociative anesthetic, which acts by
blocking the excitatory receptor N-methyl-d-aspartate receptor (NMDA). It functions to inhibit …

Therapeutic medications for the treatment of depression have serious limitations, particularly
delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic …

Over the past 50 years, ketamine has solidified its position in both human and veterinary
medicine as an important anesthetic with many uses. More recently, ketamine has been …